MedTrace Logo

Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid

NCT06479018 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-06-27

No results posted yet for this study

Summary

Bullous pemphigoid (BP) is the most frequent autoimmune skin disease and mainly affects elderly individuals. BP classically manifests with tense blisters over urticarial plaques on the trunk and extremities accompanied by intense itches. However, BP is characterized by a large spectrum of clinical presentations allowing to distinguish between typical (with blisters) and atypical forms (non bullous, mucosal damage).

High potency topical steroids and systemic steroids are the current first line intention treatments. While very efficient, these therapies are non-targeted and cause numerous side-effects, especially in these elderly patients that are the most affected. Furthermore, around 30% of BP patients will relapse during the first year of treatment when corticotherapy is decreased or stopped.

The investigators and others have highlighted the presence of Il-17 family belonging-inflammatory cytokines in BP patients. Their functions in the amplification of the inflammatory response and in the mechanisms of relapse have to be precisely determined in order to develop innovative therapeutic approaches and to move forwards precision medicine.

Conditions

  • Bullous Pemphigoid

Interventions

BIOLOGICAL

Blood sampling

Venous blood sampling will be carried out for each patient included in the study.

BIOLOGICAL

Liquid bubble sampling

Liquid bubble sampling will be carried out for each patients with Bullous Pemphigoid included in the study.

PROCEDURE

Cutaneous biopsy

At least the first cutaneous biopsy will be carried out for each patients with Bullous Pemphigoid included in the study.

Sponsors & Collaborators

  • CHU de Reims

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2025-01-10
Completion
2026-01-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06479018 on ClinicalTrials.gov